What is Androgenetic Alopecia?
Androgenetic alopecia (AGA), also known as hereditary hair loss, is one of the most common hair conditions worldwide with chronic and progressive progression. Up to 50% of women and 80% of men are affected during their lifetime. [7] In the USA alone, 30 million women and 50 million men suffer from AGA [1], while in Switzerland, over 50% of men over 65 are affected. [8] In men, hereditary hair loss typically presents as a receding hairline at the temples and hair loss at the crown, while in women AGA usually manifests differently: as even thinning in the crown area with preserved frontal hairline, as a widening part line, or as thinning at the temples. [2] Which figures exist for Switzerland, and where the data is thin, is shown on the page hair loss in Switzerland in numbers.
Hair loss mainly occurs on the upper scalp, where the scalp lies over a tighter tissue layer (galea aponeurotica). The affected areas show three typical characteristics: the hair follicles become smaller (miniaturization), more hairs are in the shedding phase, and the growth phase shortens, leading to visible hair loss.
Hair Follicle Miniaturization
The most important feature of AGA is hair follicle miniaturization. The affected hair follicles become smaller with each hair cycle. The hairs become progressively finer and thinner until they barely grow visibly from the scalp. Technically, this is called the transformation from terminal (thick) hairs to vellus hairs (fine hairs).
Miniaturization doesn't occur during hair growth. An affected hair has the same thickness from tip to root. Instead, the shrinking happens during the transition to a new hair cycle: After an old hair has fallen out, a new hair follicle forms. In AGA, this new follicle is smaller than the previous one.
Miniaturization affects not only the follicle itself but also the surrounding tissue. The sheath around the follicle thickens and scar tissue forms. These changes make it difficult for the hair follicles to return to their original size. This is one reason why hair loss progresses.
In affected individuals, the sheaths around the hair follicles are thickened. The thickening is measurable, a sign of beginning scar formation. [3] These thickenings take up the space that hair follicles need to grow. Over time, more scar tissue forms, further constricting the follicles and permanently limiting their growth.
More Shedding Than Growing Hairs
Besides miniaturization, AGA also shows an altered ratio between growing and shedding hairs. Each hair goes through a natural cycle: it grows (growth phase), transitions to a resting phase, and finally sheds (shedding phase). After that, a new follicle forms and growth begins anew. A complete cycle normally lasts two to eight years. [10]
In healthy scalps, about 9% of hairs are in the resting phase, the vast majority in the growth phase. [10] This cycle repeats continuously. Hair loss conditions can often be identified by the ratio between growing and shedding hairs.
A common reference value is one resting hair for about every twelve growing hairs, so just under 8% in the resting phase. In men with AGA, the ratio can shift to one for every five. About one hair in six is then resting, roughly 17%. [9]
Additionally, the growth phase of affected hairs shortens. Instead of growing for several years, they sometimes only grow for months. That's why many affected people notice short hairs at the hairline or crown that never grow longer than a few centimeters.
The Role of Genetics and DHT
AGA has a strong hereditary component. Men whose fathers have hair loss carry a 2.5-fold higher risk of hair loss. [4] In affected women too, hair loss often runs in the family. The exact genes are not yet fully known. Likely several genes play together, which is why inheritance is complex. [9]
Hormones play a central role. Already in the 1940s, it was shown that men without sex hormones (through castration) do not develop hereditary hair loss as long as they receive no testosterone. [5] [9]
Later, scientists identified an important hormonal factor: dihydrotestosterone (DHT). DHT is formed from testosterone and plays a central role in androgenetic alopecia. In bald areas, more DHT is often found than in healthy areas. [6] [9] Medications that lower DHT can stabilize or improve the course in many affected men. [9]
DHT is formed when the enzyme 5-alpha-reductase converts testosterone. There are different forms of this enzyme in different tissues (skin, brain, prostate).
In hair loss, mainly type II of this enzyme is involved. Differences in its activity have been observed between balding and non-balding areas. Men with a gene mutation who cannot form the type II enzyme typically do not develop androgenetic alopecia. Medications like finasteride block this enzyme and are therefore used in androgenetic alopecia. [9]
To work, DHT must bind to androgen receptors on cells. So hair loss requires three things: testosterone, the enzyme 5-alpha-reductase type II, and androgen receptors.
DHT binds about 5 times more strongly to these receptors than testosterone. [9] That's why it has a greater influence on hair follicles. In affected individuals, the follicles react particularly sensitively to DHT, a genetically determined hypersensitivity.
What We Don't Yet Understand
Despite decades of research, many questions remain open: Which genes are exactly involved? Why does DHT increase in some areas? How exactly does DHT lead to miniaturization? Why does DHT promote body hair growth but cause scalp hair loss? Why does hair loss often follow a pattern?
Research is now also investigating other factors like PPAR signaling pathways and retinoid receptors. [11] Stress can trigger diffuse shedding through a different pattern, telogen effluvium. [10] A hypothetical model suggests that chronic scalp tension, inflammation and scarring contribute and that DHT does not directly shrink follicles. This is not yet proven. [7]
Treatment Approaches
Most treatments aim to keep more hairs in the growth phase and slow or partly reverse miniaturization. Finasteride for hair loss inhibits the enzyme that converts testosterone to DHT and is well studied in male androgenetic alopecia. Studies show stabilization or improvement in many men; individual response depends on stage and physician assessment.
In Switzerland, the mediX guidelines for general practitioners describe how to approach hair loss and recommend individual medical advice. [8] Both medications like finasteride in Switzerland and correct minoxidil application as well as other approaches are considered. Modern online treatments can make access to physician assessment and established therapies easier. Current research is also investigating new approaches: combating inflammation, activating growth signals, or reducing mechanical tension in the scalp.
Facts and figures
- Up to 80% of men and 50% of women are affected by androgenetic alopecia during their lifetime. [7]
- A 2.5-fold higher risk applies to men whose fathers have hair loss. [4]
- DHT binds about 5 times more strongly to androgen receptors than testosterone. [9]
- One shedding hair for every 12 growing ones is the normal ratio, and in men with androgenetic alopecia it can rise to one in five. [9]
- 2 to 8 years is how long a complete hair cycle usually lasts. [10]
Frequently asked questions
What is the most common cause of hair loss in men?
The most common cause is androgenetic alopecia, which is hereditary hair loss. Up to 80% of men are affected during their lifetime. A receding hairline at the temples and thinning on the crown are typical.
Is hair loss hereditary?
Hereditary hair loss has a strong genetic component. Men whose fathers have hair loss carry a 2.5-fold higher risk. Exactly which genes are involved is not yet fully understood.
What role does DHT play in hair loss?
Dihydrotestosterone (DHT) is formed from testosterone by the enzyme 5-alpha reductase type II and binds about 5 times more strongly to androgen receptors. In people with a predisposition, hair follicles become smaller with each cycle until only fine vellus hairs grow.
Can stress cause hair loss?
Major stress can trigger telogen effluvium, a diffuse shedding that often starts months after the trigger. Stress does not cause hereditary hair loss, however.
When should I have hair loss checked by a doctor?
If hair loss starts suddenly or in patches, or the scalp is inflamed, have it checked in person by a dermatologist. If gradual hair loss lasts for months or worries you, an online assessment is also possible. In Switzerland, the mediX guidelines describe the approach for GPs.
References
- [1]National Institutes of Health. (2024). Androgenetic Alopecia Statistics. MedlinePlus Genetics (U.S. National Library of Medicine). medlineplus.gov (Accessed 13.10.2026)
- [2]Herskovitz I, Tosti A. (2013). Female pattern hair loss. International Journal of Endocrinology and Metabolism. doi.org/10.5812/ijem.9860
- [3]Jaworsky C, Kligman A, Murphy G. (1992). Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. British Journal of Dermatology. doi.org/10.1111/j.1365-2133.1992.tb00121.x
- [4]Chumlea WC, Rhodes T, Girman CJ, et al. (2004). Family History and Risk of Hair Loss. Dermatology. doi.org/10.1159/000078584
- [5]Hamilton JB. (1942). Male hormone stimulation is prerequisite and an incitant in common baldness. American Journal of Anatomy. doi.org/10.1002/aja.1000710306
- [6]Trüeb RM. (2002). Molecular mechanisms of androgenetic alopecia. Experimental Gerontology. doi.org/10.1016/s0531-5565(02)00093-1
- [7]English RS Jr. (2018). A hypothetical pathogenesis model for androgenic alopecia: clarifying the dihydrotestosterone paradox and rate-limiting recovery factors. Medical Hypotheses. doi.org/10.1016/j.mehy.2017.12.027
- [8]mediX Schweiz. (2024). Haarausfall – Guidelines für Hausärzte. mediX Ärztenetze Schweiz. medix.ch (Accessed 14.08.2025)
- [9]Asfour L, Cranwell W, Sinclair R. (2023). Male Androgenetic Alopecia. Endotext (NCBI Bookshelf). ncbi.nlm.nih.gov (Accessed 13.10.2026)
- [10]Natarelli N, Gahoonia N, Sivamani RK. (2023). Integrative and Mechanistic Approach to the Hair Growth Cycle and Hair Loss. Journal of Clinical Medicine. doi.org/10.3390/jcm12030893
- [11]Ho BS, Vaz C, Ramasamy S, et al. (2019). Progressive expression of PPARGC1α is associated with hair miniaturization in androgenetic alopecia. Scientific Reports. doi.org/10.1038/s41598-019-43998-7
Our guides are based on scientific sources, cited in the text. Learn about our standards
